Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating muscle weakness that worsens with use and improves with rest. The hallmark involves muscles that control eye movement, facial expression, swallowing, speech, and limb function. Approximately 60,000 to 75,000 Americans live with MG per the NINDS, with a bimodal age distribution — early-onset disease more common in women under 40 and late-onset disease more common in men over 50. The therapeutic landscape has expanded substantially in the past five years, with several new biologic agents joining traditional treatments.
The Neuromuscular Junction
MG involves antibodies that disrupt communication at the neuromuscular junction — the synapse where motor nerves signal muscles to contract. About 85 percent of generalized MG patients have antibodies against the acetylcholine receptor (AChR). Roughly 5 to 8 percent have antibodies against muscle-specific kinase (MuSK), and another 1 to 4 percent have antibodies against LRP4. About 10 percent are seronegative on standard testing despite a clinical picture of MG.
Whatever the specific antibody, the result is impaired neuromuscular transmission — the muscle does not receive enough signal to contract reliably. Repeated activation depletes the available signal, producing the characteristic fatigability.
Symptoms and Their Pattern
Ocular symptoms — drooping eyelids (ptosis) and double vision (diplopia) — are the presenting feature in about 50 percent of patients and eventually develop in over 90 percent. Symptoms typically worsen later in the day or after sustained eye use like reading or driving.
Bulbar symptoms — slurred or nasal speech, difficulty swallowing, choking on liquids, weakness when chewing — affect a significant subset and can be the dominant manifestation in MuSK-positive disease. Limb weakness, typically proximal (shoulders, hips), affects most patients with generalized MG. Neck flexor weakness producing head drop and respiratory muscle weakness in severe cases complete the picture.
The fatigable pattern is characteristic. Holding the arms outstretched for 60 to 120 seconds reproduces weakness. Sustained upgaze brings out ptosis. Ice on a drooping eyelid for 2 minutes often improves it transiently — the ice pack test is a simple bedside maneuver per Cleveland Clinic.
Diagnosis
Diagnosis combines clinical features, antibody testing, and electrophysiology. AChR antibody testing is the first-line lab; if negative in suspected generalized MG, MuSK and LRP4 antibody testing follows.
Repetitive nerve stimulation shows decremental response in about 75 percent of generalized MG patients. Single-fiber EMG, the most sensitive test, shows increased jitter in over 95 percent of MG patients but requires specialized expertise. Edrophonium (Tensilon) testing has fallen out of favor due to safety concerns and is rarely used today.
CT or MRI of the chest is mandatory at diagnosis to evaluate for thymoma, which occurs in 10 to 15 percent of MG patients and changes management. Thyroid function should be checked given the autoimmune association. Per PMC reviews, autoimmune diseases including thyroid disease, lupus, and rheumatoid arthritis cluster more often in MG patients.
Symptomatic Treatment
Pyridostigmine (Mestinon) is an acetylcholinesterase inhibitor that boosts available acetylcholine at the neuromuscular junction. It is typically the first treatment, providing symptomatic relief without addressing the underlying autoimmunity. Doses of 30 to 90 mg every 4 to 6 hours are common; higher doses can produce cholinergic side effects (cramping, diarrhea, salivation, muscle twitching).
Pyridostigmine is generally less effective in MuSK-positive MG and may even worsen symptoms in some MuSK patients. Most patients ultimately need immunomodulatory therapy in addition to or instead of pyridostigmine.
Immunomodulatory Therapy
Corticosteroids (prednisone) are commonly used to suppress the autoimmune process, often producing dramatic improvement. Initial dosing requires care — high-dose prednisone can cause transient worsening (the “steroid dip”) in the first 1 to 3 weeks, occasionally precipitating crisis. Many neurologists start steroids slowly or in hospital for moderate-to-severe disease.
Steroid-sparing immunosuppressants — azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus — allow long-term tapering of steroids. Onset of benefit typically takes 6 to 12 months for azathioprine and mycophenolate.
For acute exacerbations and crisis, plasma exchange (PLEX) and intravenous immunoglobulin (IVIG) work within days to weeks and are used as bridges to slower-acting therapies.
Rituximab — particularly effective in MuSK-positive MG — is increasingly used. Newer biologics include eculizumab and ravulizumab (complement inhibitors), efgartigimod (FcRn inhibitor that lowers IgG levels including pathogenic antibodies), rozanolixizumab (FcRn inhibitor), and zilucoplan (complement inhibitor). Annual costs for these newer agents typically run $200,000 to $700,000 retail, with insurance and assistance programs reducing patient out-of-pocket significantly. Our healthcare costs overview covers strategies for managing high-cost specialty medications.
Thymectomy
Surgical removal of the thymus has been a treatment option for decades, but its role was clarified by the MGTX trial (2016, with extension data through 2019) showing improved outcomes and reduced steroid use in AChR-positive patients aged 18 to 65 with generalized MG, even without thymoma. Patients with thymoma should always have it surgically removed if feasible.
Thymectomy benefits emerge over months to years. Robotic and minimally invasive thoracoscopic approaches have reduced the morbidity of the procedure compared to traditional sternotomy.
Myasthenic Crisis
Myasthenic crisis is severe weakness affecting respiratory muscles, requiring intubation or non-invasive ventilation. About 15 to 20 percent of MG patients experience crisis in their lifetime, most often within the first 2 years of diagnosis. Triggers include infection (especially respiratory), surgery, certain medications, pregnancy, stress, and sometimes onset or escalation of corticosteroids.
Medications to avoid in MG include certain antibiotics (aminoglycosides, fluoroquinolones, telithromycin, macrolides — with caution), beta-blockers (relative caution), magnesium (intravenous), neuromuscular blocking agents, certain anesthetics, and statins (occasionally). Always inform any new clinician about MG, especially when prescribing or before any anesthesia.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience severe shortness of breath, inability to clear secretions, choking that does not resolve, severe weakness preventing standing or holding the head up, or rapid worsening of swallowing or speech. Myasthenic crisis is a medical emergency requiring ICU-level care, often with non-invasive or invasive ventilation. Cholinergic crisis from pyridostigmine overdose can mimic myasthenic crisis but with extra autonomic symptoms (excessive salivation, sweating, GI symptoms, small pupils) — both warrant urgent evaluation.
Living With Myasthenia Gravis
Routines accommodate fatigue patterns. Important activities are scheduled when symptoms tend to be best, often morning. Rest breaks are integrated rather than reactive. Many patients track symptom diaries to identify patterns and triggers.
Heat worsens MG for many patients. Hot weather, hot showers, and saunas can trigger fatigue. Air conditioning, cool clothing, and adjusting outdoor activities to cooler times help.
Vaccination is generally recommended (avoiding live vaccines on strong immunosuppression). Pregnancy planning and management benefits from coordination between neurology and maternal-fetal medicine — most women have stable or improved MG during pregnancy with careful monitoring. Our medical conditions overview covers chronic disease management more broadly.
When to See a Doctor
New unexplained drooping eyelid, double vision, slurred speech, swallowing difficulty, or fatigable weakness warrants neurology evaluation. Established MG patients should have low threshold for evaluation of new or worsening weakness, respiratory symptoms, or before any planned surgery or new medication.
Many doctors recommend MG-specific Medic Alert identification given the medication interactions and emergency considerations. Patient organizations like the Myasthenia Gravis Foundation of America provide resources and connect patients to specialty centers.
Frequently Asked Questions
Is myasthenia gravis fatal?
With modern treatment, mortality has fallen dramatically — from over 30 percent in the early 20th century to under 5 percent today. Myasthenic crisis remains the main acute risk and is treatable in well-equipped centers. Most patients live near-normal lifespans.
Can myasthenia gravis go into remission?
Yes. With effective treatment, many patients achieve sustained minimal manifestations or pharmacologic remission. Some achieve remission off all therapy, though this is less common. Remission rates are higher after thymectomy in AChR-positive patients than without.
Is myasthenia gravis hereditary?
Acquired autoimmune myasthenia gravis is not directly inherited. Genetic susceptibility to autoimmunity in general plays a role, and clusters of autoimmune disease occur in families. Congenital myasthenic syndromes, distinct from autoimmune MG, are inherited and present in childhood.
What medications should I avoid with myasthenia gravis?
Several medications can worsen MG, including aminoglycoside and fluoroquinolone antibiotics, intravenous magnesium, certain anesthetics, neuromuscular blocking agents, and some cardiac drugs. Always inform clinicians about MG before any new prescription or procedure. The MGFA maintains a regularly updated cautionary medications list.
The Bottom Line
Myasthenia gravis is one of the more treatable autoimmune neurological diseases, with multiple effective therapies and an expanding pipeline. Pyridostigmine for symptomatic relief, immunosuppression for autoimmune control, and thymectomy in appropriate candidates form the foundation. Newer biologics — FcRn inhibitors and complement inhibitors — have created options for patients who don’t respond well to traditional treatment, though at substantial cost. Recognizing myasthenic crisis as an emergency, knowing which medications to avoid, and partnering with a neurologist comfortable with MG produce the best outcomes. Most patients today achieve sustained good control with normal life expectancy, a far cry from the disease’s grim historical reputation.